Trials / Completed
CompletedNCT04665648
Clinical Efficacy and sAfety of Intravenous Infusion of Nicorandil During Primary Percutaneous Coronary Intervention
Impact of Intravenous Administration of Nicorandil as Adjuncts to Reperfusion Treatment for Acute ST Segment Elevation Myocardial Infarction: a Multi-center Randomized Controlled Trial
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 1,500 (actual)
- Sponsor
- Fudan University · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The investigators evaluate the efficacy and safety of intravenous administration of nicorandil as adjuncts to reperfusion treatment in acute ST-segment elevation acute myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nicorandil | 6 mg nicorandil iv. just before coronary intervention, 6mg/h ivgtt. up to 48h after coronary intervention |
| DRUG | Placebo | placebo iv. just before coronary intervention, ivgtt. up to 48h after coronary intervention |
Timeline
- Start date
- 2021-06-01
- Primary completion
- 2024-12-31
- Completion
- 2024-12-31
- First posted
- 2020-12-11
- Last updated
- 2025-03-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04665648. Inclusion in this directory is not an endorsement.